Sophie Binay

Sophie has over 20 years’ experience in start-ups and mid-size companies within the biotechnology areas. She has a strong expertise in oncology, immunology and virology. Sophie has managed a number of innovative R&D projects from the proof-of-concept to early clinical development. In her previous positions, Sophie was Vice-President Research and Early Clinical Development at PEP-Therapy, responsible for the development of peptide drug candidates and their biomarkers up to clinical trials. She was responsible for nonclinical R&D activities at InnaVirVax, developing innovative immune-based treatments for infectious diseases. She was Head of translational programs in oncology at Gustave Roussy Cancer Center, where she coordinated research programs and implemented innovative technology platforms dedicated to translational research. During her carrier, Sophie held various positions, at INSERM, CEA, Centre d’Immunologie Pierre Fabre, VIRalliance and Stallergenes. Sophie holds a PhD in immunology from Paris VII Denis Diderot university. She is (co-)author of about 20 scientific publications and co-inventor of 9 patents.